Back

Evaluation of single-cell RNA profiling technologies using FFPE, fresh, and frozen ccRCC tumor specimens

Xirenayi, S.; Camp, S. Y.; Garza, A. E.; Rustagi, Y.; Pimenta, E.; Shannon, E.; Nag, A.; Betherman, A.; Anselmo, A.; Trowbridge, R.; Thorner, A. R.; Park, J.; Bi, K.; Van Allen, E. M.

2025-11-28 cancer biology
10.1101/2025.11.25.690485 bioRxiv
Show abstract

The application of single-cell transcriptomic approaches has deepened our understanding of tumor heterogeneity, immune dynamics, and molecular programs underlying therapy response. The recent development of fixation-compatible single-cell platforms, such as 10x Genomics Flex, offers the opportunity to profile archived formalin-fixed, paraffin-embedded (FFPE) specimens, expanding access to clinically valuable samples. However, most benchmarking studies of recent single-cell RNA sequencing (scRNA-seq) technologies have relied on peripheral blood mononuclear cells, limiting their relevance to human tissues. Here, we compared three 10x single-cell RNA profiling methods, fresh tumor scRNA-seq, flash-frozen single-nucleus Multiome, and FFPE single-nucleus Flex (snFlex), using clear cell renal cell carcinoma (ccRCC) biopsies. Across methods, we observed broadly consistent cell type-specific transcriptional profiles among major ccRCC cell populations. Despite lower gene and UMI counts, snFlex reliably identified fine-grained states within CD8+ T cells, tumor-associated macrophages, and tumor compartments, comparable to those detected by scRNA-seq. Together, these findings highlight the distinct advantages of each technology depending on sample preservation type and study design, providing practical guidance for single-cell RNA profiling technology selection in translational studies using human tumor biopsies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Genome Medicine
154 papers in training set
Top 0.1%
18.6%
2
Cell Reports Medicine
140 papers in training set
Top 0.1%
10.1%
3
Laboratory Investigation
13 papers in training set
Top 0.1%
8.4%
4
Cancer Research Communications
46 papers in training set
Top 0.1%
6.3%
5
Nature Communications
4913 papers in training set
Top 33%
4.8%
6
Scientific Reports
3102 papers in training set
Top 31%
4.0%
50% of probability mass above
7
JCI Insight
241 papers in training set
Top 1%
3.6%
8
Journal of Translational Medicine
46 papers in training set
Top 0.2%
3.6%
9
PLOS ONE
4510 papers in training set
Top 46%
2.4%
10
Modern Pathology
21 papers in training set
Top 0.2%
1.8%
11
Clinical Cancer Research
58 papers in training set
Top 1.0%
1.7%
12
npj Precision Oncology
48 papers in training set
Top 0.8%
1.3%
13
eLife
5422 papers in training set
Top 49%
1.2%
14
eBioMedicine
130 papers in training set
Top 2%
1.2%
15
Frontiers in Oncology
95 papers in training set
Top 3%
1.2%
16
International Journal of Molecular Sciences
453 papers in training set
Top 12%
0.9%
17
Cancers
200 papers in training set
Top 4%
0.9%
18
BMC Genomics
328 papers in training set
Top 5%
0.9%
19
Nature Biotechnology
147 papers in training set
Top 6%
0.9%
20
npj Genomic Medicine
33 papers in training set
Top 0.7%
0.9%
21
Genome Biology
555 papers in training set
Top 7%
0.8%
22
Molecular Cancer
14 papers in training set
Top 0.8%
0.8%
23
Communications Biology
886 papers in training set
Top 21%
0.8%
24
Cell Reports
1338 papers in training set
Top 32%
0.8%
25
Nucleic Acids Research
1128 papers in training set
Top 18%
0.7%
26
Science Translational Medicine
111 papers in training set
Top 6%
0.7%
27
Genome Research
409 papers in training set
Top 4%
0.7%
28
Cancer Discovery
61 papers in training set
Top 2%
0.6%